Page 41 - Demo

Panitumumab and chemoradiation for inoperable pancreatic cancer392they are presumably better tolerated than CRT. Yet the efficacy of these approaches compared with the efficacy of CRT for LAPC has to be established. The above local treatment possibilities illustrate the challenging options for patients with LAPC. In conclusion, we report that the use of panitumumab at a MTD of 1.5 mg/kg can be safely added to gemcitabine-based CRT in patients with LAPC. The observed PFS and OS rates suggest some efficacy. These observations support the further evaluation of this combination in a phase II study along with the search of predictive biomarkers to allow future selection of patients with an increased chance of experiencing clinical benefit from this type of combination therapy. Table 4. Trials of CRT + targeted therapies for pancreatic cancerCharacteristics of CRT trials in combination with targeted therapyRef. Study treatment Patients, n Median TTP (mo)Median survival (mo)This study, 2015 RT(50.4 Gy)+GEM+PAN-GEM 13 8.9 MTD cohort: 11.812.3 MTD cohort:17.0Kim, 2012 (abstr) (32) PAN+5FU/CAP+RT (50.4 Gy)-GEM+PAN-PAN51 7.4 12.1Rembielak et al. (33) CET+RT (50.4 Gy) 21 5.1 7.5Crane et al. (34) CET+GEM+OX- CAP+CET+RT (50.4 Gy)69 12.5 19.2Crane et al. (35) CAP+RT (50.4 Gy)+BEV-GEM+BEV. 82 8.9 11.9Chiorean et al. (36) SOR + GEM + RT (50 Gy)-GEM 25 10.6 11.4Morak et al. (28) UFT + L + C + RT (50 Gy) 83 6.9 10.6Czito et al. (37) E + BEV + RT (50.4 Gy) 9 a a Abbreviations: BEV, bevacizumab; C, celecoxib; CAP, capecitabine; CET, cetuximab; GEM, gemcitabine; E, Erlotinib; L, leucovorin; OX, oxaliplatin; PAN, panitumumab; SOR, sorafenib; UFT, Uracil/Tegafur. aMed TTP and OS not mentioned in abstract, study is not publishedDisclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed.Grant Support Amgen provided financial support for this work.